Holen Sie sich die Stockscreener-App
93.24
0.61%
-1.07
Schlusskurs vom Vortag:
$94.31
Offen:
$93.59
24-Stunden-Volumen:
97,171
Relative Volume:
0.08
Marktkapitalisierung:
$6.18B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-116.25M
KGV:
-38.99
EPS:
-2.3912
Netto-Cashflow:
$-91.19M
1W Leistung:
+2.29%
1M Leistung:
-5.15%
6M Leistung:
+178.54%
1J Leistung:
+483.99%
1-Tages-Spanne:
$92.84
$94.85
1-Wochen-Bereich:
$87.68
$96.44
52-Wochen-Spanne:
$14.66
$115.52
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Firmenname
Oruka Therapeutics Inc
Sektor
Branche
Telefon
650-606-7910
Adresse
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
93.29 | 6.24B | 0 | -116.25M | -91.19M | -2.3912 |
VRTX
Vertex Pharmaceuticals Inc
|
521.93 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.00 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,002.66 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.46 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.90 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Piper Sandler | Overweight |
| 2025-11-13 | Eingeleitet | Jefferies | Buy |
| 2025-10-27 | Eingeleitet | Guggenheim | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-11 | Eingeleitet | Stifel | Buy |
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | Leerink Partners | Outperform |
| 2024-09-16 | Eingeleitet | TD Cowen | Buy |
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-02-27 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Eingeleitet | Dawson James | Buy |
Alle ansehen
Oruka Therapeutics Inc Aktie (ORKA) Neueste Nachrichten
ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits
About Oruka Therapeutics Inc aStock - Coinbase
ORKA News | ORUKA THERAPEUTICS INC (NASDAQ:ORKA) - ChartMill
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy - Investing.com UK
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Oruka Therapeutics CEO Klein sells $6.8m in stock By Investing.com - Investing.com South Africa
Oruka Therapeutics COO Laura Sandler sells $459,101 in stock By Investing.com - Investing.com South Africa
Oruka Therapeutics(ORKA.US) Officer Sells US$6.89 Million in Common Stock - Moomoo
Oruka Therapeutics COO Laura Sandler sells $459,101 in stock - Investing.com
Oruka Therapeutics CEO Klein sells $6.8m in stock - Investing.com
Oruka Therapeutics (NASDAQ: ORKA) Launches Up to $500M Common Stock Offering via TD Cowen - Kalkine Media
Oruka Therapeutics Inc (ORKA) Stock Price, Quote, News & History - Benzinga
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know - Yahoo Finance
Oruka Therapeutics Inc aStock (AORKA) Price Prediction for 2026 to 2031 - bybit.com
Oruka Therapeutics names Todd Edwards as chief commercial officer By Investing.com - Investing.com India
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer with Detailed Compensation Package - Kalkine Media
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer - Barchart.com
Oruka Therapeutics Appoints Todd Edwards As Chief Commercial Officer - TradingView
Oruka Therapeutics Files $1 Billion Mixed Shelf - marketscreener.com
Oruka Therapeutics Inc aStock Price: AORKA Live Price Today | AORKA Market Cap & Chart Analysis - bybit.com
Show Me The Money: ORKA Makes A Splash With A 500%+ Gain; More Catalysts Ahead - RTTNews
Oruka (ORKA) Outlook: Finishes 4.40% Lower at $104.86 in the Current Update; Level Watch: Support at $99.62 and Resistance at $110.10 Frame the Range at the CloseFRAMA Signal - Vinanet
RTW Investments, LP Expands Oruka Therapeutics (ORKA) Stake with Strategic Add - GuruFocus
Oruka (ORKA) Earnings Snapshot: The Available Earnings Metric Delivers a Miss in the Available Record; Post-Report: Shares Finish 3.00% Down for the Current SessionEarnings Cycle Outlook - Vinanet
Preferred dividends of Oruka Therapeutics, Inc. – HAM:HQ1 - TradingView
Oruka Therapeutics, Inc. Income Statement – HAM:HQ1 - TradingView
Oruka Therapeutics (ORKA) Is Up 8.0% After Wider Q2 Net LossesHas The Bull Case Changed? - simplywall.st
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Oruka Therapeutics CMO Joana Goncalves sells $782,882 in stock - Investing.com
Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 52-Week HighWhat's Next? - MarketBeat
ORKA Q2 2026 Earnings: Wider Loss Reflects R&D Investment as Pre-Revenue Biotech Advances PipelineEarnings Power Value - Vinanet
Biotech Stocks At 52-Week HighsETON +44%, DXCM, ORKA, CON, ATAI - RTTNews
Oruka Therapeutics (NASDAQ:ORKA) Cut to "Sell" at Wall Street Zen - MarketBeat
LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $175 - Moomoo
Oruka Therapeutics stock hits 52-week high at 109.56 USD By Investing.com - Investing.com South Africa
Oruka Therapeutics GC Paul Quinlan sells $5.64m stock By Investing.com - Investing.com Canada
Oruka Therapeutics GC Paul Quinlan sells $5.64m stock - Investing.com
Oruka Therapeutics senior vice president Arjun Agarwal sells $1.06m By Investing.com - Investing.com Australia
Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 10,000 Shares of Stock - MarketBeat
Oruka Therapeutics senior vice president Arjun Agarwal sells $1.06m - Investing.com
Oruka Therapeutics Insider Sold Shares Worth $5,641,409, According to a Recent SEC Filing - marketscreener.com
Oruka Therapeutics Insider Sold Shares Worth $1,066,572, According to a Recent SEC Filing - marketscreener.com
Oruka Therapeutics (ORKA): Venrock group reports 7.4% ownership stake - Stock Titan
ORKA (ORKA) insider Paul Quinlan files to sell 71,000 shares via option exercise - Stock Titan
Viking Global group discloses 1.50M Oruka (ORKA) shares on amended 13G - Stock Titan
Oruka Therapeutics stock hits 52-week high at 109.56 USD - Investing.com
Oruka Therapeutics (ORKA) gains 5.2% stake holder with 3.14M shares - Stock Titan
Handelsbanken Fonder AB Purchases Shares of 160,900 Oruka Therapeutics, Inc. $ORKA - MarketBeat
Sei Investments Co. Raises Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Finanzdaten der Oruka Therapeutics Inc-Aktie (ORKA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oruka Therapeutics Inc-Aktie (ORKA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sandler Laura Lee | Chief Operating Officer |
Sep 01 '26 |
Sale |
91.82 |
5,000 |
459,101 |
236,384 |
| Klein Lawrence Otto | Chief Executive Officer |
Sep 01 '26 |
Option Exercise |
7.80 |
75,000 |
585,000 |
1,000,580 |
| Klein Lawrence Otto | Chief Executive Officer |
Sep 01 '26 |
Sale |
91.83 |
75,000 |
6,887,484 |
925,580 |
1.30%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):